Most nootropic claims involve a compound doing something to the brain directly. Lion's mane's most interesting compounds don't act as neurotransmitters at all — they stimulate the brain's own nerve growth factor synthesis.
Following July's reishi profile, this month's fungi entry is Hericium erinaceus — lion's mane, named for the cascading white spines that make it look nothing like a typical mushroom. It's had genuine culinary and medicinal use across East Asia for centuries, but the reason it's become one of the more talked-about compounds in cognitive health circles is a specific, unusual mechanism.
Lion's mane contains two distinct classes of active compound depending on which part of the fungus you're using. Hericenones come from the fruiting body — the visible mushroom. Erinacines come from the mycelium — the root-like network the fungus grows through its substrate. This matters clinically, because most of the low-quality mushroom products on the market use mycelium grown on grain, which dilutes active content with starch filler. The distinction between fruiting-body and mycelium-based extracts is one of the single biggest quality variables in this entire category.
Nerve growth factor (NGF) is a protein essential for the survival, maintenance and growth of neurons — a deficiency in NGF signalling is implicated in the pathology of neurodegenerative conditions including Alzheimer's disease. The problem is that NGF itself is a large protein molecule that can't cross the blood-brain barrier if given directly, which is why supplementing NGF itself has never been a viable therapeutic route.
Hericenones and erinacines solve this differently — they are small molecular weight compounds capable of crossing the blood-brain barrier themselves, and once there, they stimulate the brain's own NGF biosynthesis. Erinacines in particular appear to have the stronger effect and better penetration. In preclinical work using amyloid-beta-injected mice and transgenic Alzheimer's models, erinacine-A-enriched extracts reduced amyloid plaque deposition and improved learning and memory measures.
This is the honest part. The mechanistic and preclinical (animal) evidence for NGF stimulation is genuinely strong and consistent. The human clinical evidence is real but thin: trials have been small, generally short in duration, and results across cognition studies have been described even by neutral reviewers (including the Alzheimer's Drug Discovery Foundation) as mixed. The most cited human trial — Mori and colleagues, 2009 — enrolled 31 Japanese adults over 50 with mild cognitive impairment, giving 2.4g/day of dried fruiting body powder for 12 weeks, and found significantly improved MMSE (cognitive screening) scores versus placebo — but the improvement diminished after supplementation stopped, suggesting an effect that requires ongoing use rather than a lasting structural change from a short course.
Cognitive trials: around 2.4–3g/day of fruiting body extract, taken consistently over 8–12 weeks minimum — this is not a same-day nootropic in the way caffeine or L-theanine can feel.
Form matters here more than almost anywhere else in this series: look specifically for fruiting-body-derived extract (for hericenones) or a dual extraction covering mycelium (for erinacines), rather than "mycelium on grain" products, which can be mostly starch by weight with a fraction of the actual active compound content of a genuine fruiting body extract.
Lion's mane doesn't have a direct biomarker "confirmation" the way a nutrient deficiency does — there's no blood test for NGF status. The more useful clinical question is whether the presenting picture fits: subjective cognitive complaints (brain fog, word-finding difficulty, mental fatigue) in the context of a broader picture that's already been worked through — ruling out thyroid dysfunction, B12/folate status, homocysteine, and inflammatory drivers via OAT and blood chemistry — rather than reaching for it as a first move before those more foundational pieces are checked.
The most honest framing: this is a compound with a genuinely elegant, well-documented mechanism, and human evidence that hasn't yet caught up to how interesting the mechanism is. Both things are true at once.
If someone's cognitive symptoms are new, worsening, or accompanied by other neurological signs, that's a reason for proper medical investigation, not a reason to start a mushroom extract and wait. Lion's mane sits appropriately as an adjunct once the more foundational and better-evidenced pieces of a cognitive picture have already been addressed.
Ask AIdan what a cognitive-support protocol should actually prioritise given your test results.
Ask AIdan → See the TDG Programme